Abstract
Hyaluronic acids (HAs) are very popular temporary fillers with a very good safety record. Improvements and adaptations in clinical use are continuing.
We have assessed the available literature to investigate the relatively new Vycross technology that uses a mixture of high- and low-molecular-weight HAs with a relatively low but varying HA concentration with enhanced crosslinking to produce a number of products that have differing clinical indications.
Original language | English |
---|---|
Pages (from-to) | 139S - 148S |
Number of pages | 10 |
Journal | Plastic and Reconstructive Surgery |
Volume | 136 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2015 |